Shilpa Medicare secures Orion for European nivolumab biosimilar commercialization and supply
Discover how Orion and Shilpa Medicare’s nivolumab biosimilar deal could reshape European oncology access, pricing and hospital procurement.
Pharma & Biotech
Medical Devices & Diagnostics
Why Optellum’s deployment at Tanner Health could matter for lung cancer risk stratification
Find out how Tanner Health’s Optellum rollout could reshape AI lung nodule triage and early lung cancer detection in regional care.
Pharma & Biotech
Nuvalent’s ALK inhibitor gets Priority Review as lung cancer treatment sequencing evolves
Nuvalent’s neladalkib has FDA Priority Review in ALK-positive lung cancer. Find out why resistance and brain metastases drive the story.
Pharma & Biotech
Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
Amgen’s Imdylltra has European approval in relapsed small cell lung cancer. Survival data now face reimbursement and adoption tests.
Pharma & Biotech
Is atypical EGFR-mutated NSCLC becoming Johnson & Johnson’s next precision oncology battleground?
Atypical EGFR lung cancer lacks clear first-line answers. Rybrevant plus Lazcluze may change that, but trial size still matters.
Pharma & Biotech
Akari Therapeutics Plc advances AKTX-101 as RNA splicing ADC targets TROP2 resistance in oncology
Discover how AKTX-101 could redefine TROP2 ADC resistance strategies in oncology. Read the full analysis now.
Pharma & Biotech
FDA clears subcutaneous RYBREVANT FASPRO for first-line EGFR+ NSCLC: What this changes for patients and providers
The U.S. Food and Drug Administration has approved Johnson & Johnson’s RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj), the first subcutaneous version of its bispecific EGFR-MET antibody therapy, for patients with EGFR-mutated non-small cell lung cancer (NSCLC). The approval spans all current RYBREVANT indications and is based on the Phase 3 PALOMA-3 study, which demonstrated comparable pharmacokinetics
Pharma & Biotech
How Indivumed’s biospecimen strategy is powering functional tumor model development
Indivumed GmbH and the Wilmot Cancer Institute at the University of Rochester Medical Center have expanded their collaboration to accelerate the development of patient-derived tumor models and AI-informed therapeutic discovery for solid tumors with high unmet clinical need. What this collaboration changes for the cancer model ecosystem The expansion of the Indivumed and University of
Pharma & Biotech
Can IDE574 reshape breast and lung cancer treatment by targeting KAT6 and KAT7?
IDEAYA Biosciences files IND for IDE574, a KAT6/7 inhibitor for breast and lung cancer. Learn how this new class may change epigenetic treatment strategies.